What are the potential interactions between ezetimibe and vascepa?

How do ezetimibe and vascepa work together in the body?
Ezetimibe reduces cholesterol absorption in the small intestine, lowering LDL cholesterol levels. Vascepa contains purified eicosapentaenoic acid (EPA) and works primarily by lowering triglycerides while also reducing inflammation in blood vessels. Their mechanisms are different so they often complement each one another when prescribed together for mixed lipid disorders.

What does clinical data show about combining these two drugs?
Limited direct clinical trials test their specific combination. Studies on EPA and ezetimibe in patients with persistent high triglycerides show reductions in LDL and triglycerides without notable adverse events. Patients who receive both usually experience the same side effects as each drug alone.

Are there known pharmacokinetic interactions?
Neither ezetimibe nor Vascepa undergoes significant cytochrome P450 metabolism. Ezetimibe is excreted mainly through bile and feces. Vascepa is metabolized to fatty acids. No pharmacokinetic overlap occurs, so plasma levels of each remain unverändert.

What side effects do patients report when taking both?
Patients who report problems usually cite gastrointestinal discomfort or muscle pain, which occurs equally in ezetimibe alone and in the combined group. No new or amplified interactions emerge from the data.